Pathos AI struck a deal for rights to a bispecific antibody drug conjugate from Alphamab that could become first in a new class of cancer drugs. Separately, the startup began a partnership with AstraZeneca on a protein degrader from the pharma company’s cancer drug pipeline. The post Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents appeared first on MedCity News .
Three recent studies, two published in JACC: Advances and a third published in JAMA Cardiology, investigate sex differences, delayed diagnosis and the effect of acoramidis on heart failure (HF)-related health status in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
ACP supports the independently developed immunization schedules of the American Academy of Pediatrics, the American Academy of Family Physicians, and the American College of Obstetricians and Gynecologists.
Ralinepag, a selective prostacyclin IP receptor agonist, significantly reduced the risk of first clinical worsening compared with placebo in patients with pulmonary arterial hypertension (PAH) but was associated with more adverse-event-related treatment discontinuations, according to results of the ADVANCE OUTCOMES trial published July 28 in The Lancet.
Both TAVR and SAVR were associated with a sustained, substantial improvement in patient-reported health status among patients with severe aortic stenosis (AS) considered at low risk, according to the seven-year outcomes of the PARTNER 3 trial published July 29 in JACC.
The recent release of the 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome marked an important step in defining evidence-based approaches to CKM prevention, risk assessment and treatment.
The University of Oxford spinout will soon launch the AI tool, which research suggests could help assess heart attack risk in patients who don’t have obstructive coronary artery disease.
The executive has led Danaher’s diagnostics business, where she helped triple operating profit during her tenure and oversaw the recent acquisition of Masimo.
The year 2025 was a landmark year for cardiogenic shock (CS) and mechanical circulatory support (MCS). Two major clinical guideline documents were published, the longest-duration follow-up data from the field's pivotal trial were released, and real-world registries continued to challenge trial generalizability.
by Samuel M. Miller, Paige DeGoursey, Kevin G. Billingsley Surgical palliative care (SPC) integrates the principles of symptom-based care and relief of suffering into traditional surgical practice. From the perspectives of a bedside nurse, surgical critical care fellow, and surgical oncologist, there are natural opportunities to incorporate these principles and in doing so, progress towards SPC becoming the standard of practice. From the perspectives of a bedside nurse, surgical critical care fellow and surgical oncologist, this Perspective by Samuel Miller, Paige DeGoursey and Kevin…
The future of health care innovation is technology that carries more of the load, so people don’t have to. The post Health Tech Promised Simplicity — Why Does It Feel Like More Work? appeared first on MedCity News .
FOR IMMEDIATE RELEASE – July 31, 2026 – Raleigh, North Carolina, Liebel-Flarsheim Company, LLC, is recalling one lot of OPTIRAY Imaging Bulk Package (IBP) 350, 500mL in vial, (Ioversol Injection 74% 350 mg iodine/ml) for intra-arterial or intra-venous use to the user level (hospitals, imaging center
[Sponsored] What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes. The post From Blind Spots to Better Outcomes: How SNF Data Transparency Strengthens LTSS appeared first on MedCity News .
In this interview, Allen J. Taylor MD, FACC and Sanjay Kaul, MBBS examine ‘Why Can’t We Prove Revascularization Is Better Than Medical Therapy for SIHD?’
Contract research organization Icon announced a multi-year collaboration with Anthropic this week to bring Claude’s AI capabilities to clinical trials.
The gap between what technology can do and how much patients trust it won’t close on its own. Here are some design decisions that build trust — and some that quietly destroy it. The post The Trust Gap in Digital Health and AI Starts With Design — Here’s How to Close It appeared first on MedCity News .
Amgen has ended development of its early-stage obesity drug AMG 513, foisting its hopes for a slice of the massive weight loss market onto the shoulders of phase 3 candidate MariTide.
In April 2026, Dräger issued a follow-up Field Safety Notice expanding the number of Atlan Anaesthesia workstation devices affected by a manufacturing defect that may result in mechanical ventilation failure.
Expedition Therapeutics has secured an oversubscribed $115 million series B financing from a line-up of big-name investors to propel its lead DPP1 inhibitor through phase 2.
Objectives This study aimed to investigate the knowledge, attitude and practice (KAP) regarding postoperative health self-management among patients undergoing percutaneous coronary intervention. Design A cross-sectional survey was conducted. Setting The study took place at Shanxi Bethune Hospital within the Department of Cardiology, encompassing both inpatient and outpatient settings. Participants A total of 500 patients who had undergone coronary interventional procedures participated in the survey. Interventions Demographic information and KAP scores were obtained using a self-administered…